Stock MDGL MADRIGAL PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Madrigal Pharmaceuticals, Inc. Stock

Equities

MDGL

US5588681057

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-31 EDT 		5-day change 1st Jan Change
236.2 USD +4.73% Intraday chart for Madrigal Pharmaceuticals, Inc. +2.87% +2.07%
05-19 Certain Common Stock of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
05-19 Certain Warrants of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI

Financials

Sales 2024 * 75.76M 103M Sales 2025 * 361M 492M Capitalization 5.03B 6.86B
Net income 2024 * -583M -795M Net income 2025 * -403M -549M EV / Sales 2024 * 57.3 x
Net cash position 2024 * 694M 945M Net cash position 2025 * 292M 398M EV / Sales 2025 * 13.1 x
P/E ratio 2024 *
-8.33 x
P/E ratio 2025 *
-13 x
Employees 376
Yield 2024 *
-
Yield 2025 *
-
Free-Float 82.63%
More Fundamentals * Assessed data

Chart Madrigal Pharmaceuticals, Inc.

Dynamic Chart

Latest news about Madrigal Pharmaceuticals, Inc.

Certain Common Stock of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
Certain Warrants of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
Certain Pre Funded Warrants of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
Certain Performance Stock Units of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
Certain Restricted Stock Units of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
Certain Options of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
Madrigal Pharmaceuticals Insider Sold Shares Worth $4,787,404, According to a Recent SEC Filing MT
B. Riley Cuts Madrigal Pharmaceuticals' Price Target to $200 From $270, Keeps Neutral Rating MT
UBS Adjusts Price Target on Madrigal Pharmaceuticals to $411 From $410, Maintains Buy Rating MT
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday MT
Madrigal Pharmaceuticals Q1 Loss Widens; Shares Fall Pre-Bell MT
Transcript : Madrigal Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024
Madrigal Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective MT
BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target MT
More news

Latest transcript on Madrigal Pharmaceuticals, Inc.

Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024
More transcripts

Analyst Recommendations on Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Insider Sold Shares Worth $4,787,404, According to a Recent SEC Filing MT
B. Riley Cuts Madrigal Pharmaceuticals' Price Target to $200 From $270, Keeps Neutral Rating MT
UBS Adjusts Price Target on Madrigal Pharmaceuticals to $411 From $410, Maintains Buy Rating MT
BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective MT
BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target MT
More recommendations

Press releases Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress AQ
Madrigal: Q1 Earnings Snapshot AQ
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates AQ
Nonalcoholic Steatohepatitis Market to Observe Impressive Growth During the Forecast Period | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Eli Lilly and Company, Madrigal Pharmaceuticals AQ
Madrigal Statement on the Passing of Dr. Stephen Harrison AQ
More press releases

News in other languages on Madrigal Pharmaceuticals, Inc.

EE.UU. - Valores a seguir en Wall Street (actualizado)
Madrigal Pharmaceuticals : Super Micro Computer, Madrigal, Tencent... les valeurs à suivre aujourd'hui à Wall Street -
Madrigal Pharmaceuticals : lève 600 millions de dollars pour le lancement de son Rezdiffra
Wall Street ouvre en baisse, les regards tournés vers la Fed
EE.UU. - Valores a seguir en Wall Street (actualizado)
More news

Quotes and Performance

1 day+4.73%
1 week+2.87%
1 month+12.14%
3 months-6.15%
6 months+10.81%
Current year+2.07%
More quotes

Highs and lows

1 week
219.39
Extreme 219.39
236.72
1 month
200.08
Extreme 200.08
250.34
Current year
168.25
Extreme 168.2462
299.98
1 year
119.76
Extreme 119.7604
299.98
3 years
52.33
Extreme 52.33
322.67
5 years
52.33
Extreme 52.33
322.67
10 years
6.60
Extreme 6.6
325.98
More quotes

Managers and Directors - Madrigal Pharmaceuticals, Inc.

Managers TitleAgeSince
Edward Chiang FOU
 Founder - 11-08-31
William Sibold CEO
 Chief Executive Officer - 23-09-07
Rebecca Taub FOU
 Founder 71 16-06-30
Members of the board TitleAgeSince
Fred Craves FOU
 Founder 78 11-08-31
Julian Baker CHM
 Chairman 57 23-06-14
Ken Bate BRD
 Director/Board Member 73 16-07-21
More insiders

ETFs positioned on Madrigal Pharmaceuticals, Inc.

Name Weight AuM 1st Jan change Investor Rating
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares 3x Long Biotechnology ETP Securities - USD
0.35% 0 M€ 0.00% -
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares -3x Short Biotechnology ETP Securities - USD
0.08% 0 M€ 0.00% -
More ETFs positioned on Madrigal Pharmaceuticals, Inc.

Quotes

Date Price Change Volume
24-05-31 236.2 +4.73% 348,452
24-05-30 225.5 +1.34% 234,490
24-05-29 222.5 -0.35% 263,607
24-05-28 223.3 -2.74% 808,191
24-05-24 229.6 -2.24% 374,487

Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm

More quotes

Company Profile

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
Biotechnology & Medical Research
Calendar
2024-08-05 - Q2 2024 Earnings Release (Projected)
Related indices
Russell 2000
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
236.2 USD
Average target price
363.9 USD
Spread / Average Target
+54.07%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MADRIGAL PHARMACEUTICALS, INC. Stock Madrigal Pharmaceuticals, Inc.
+2.07% 5.03B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.60% 106B
BIONTECH SE Stock BioNTech SE
-4.68% 24.28B
ARGENX SE Stock argenx SE
-0.82% 21.96B
GENMAB A/S Stock Genmab A/S
-10.12% 18.16B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.12% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.47% 15.56B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.77% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.58% 12.27B
INSMED INCORPORATED Stock Insmed Incorporated
+77.64% 8.87B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MDGL Stock